Cell-free DNA concentration in patients with clinical or mammographic suspicion of breast cancer
| العنوان: | Cell-free DNA concentration in patients with clinical or mammographic suspicion of breast cancer |
|---|---|
| المؤلفون: | Yuval Mizrakli, Amos Douvdevani, Maia Rosenthal, Victor Novack, Samuel Ariad, Ravit Agassi, Reut Riff, Shaked Yarza, David Czeiger, Irena Lazarev, Michal Peled |
| المصدر: | Scientific Reports, Vol 10, Iss 1, Pp 1-9 (2020) Scientific Reports |
| بيانات النشر: | Nature Publishing Group, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, Receptor, ErbB-2, medicine.medical_treatment, lcsh:Medicine, Circulating Tumor DNA, Prognostic markers, Breast cancer, 0302 clinical medicine, Medicine, Prospective Studies, Prospective cohort study, lcsh:Science, Aged, 80 and over, Multidisciplinary, medicine.diagnostic_test, Middle Aged, Prognosis, Combined Modality Therapy, Tumor Burden, Receptors, Estrogen, Cell-free fetal DNA, Female, Receptors, Progesterone, Cell-Free Nucleic Acids, Mammography, Adult, medicine.medical_specialty, Adolescent, Breast Neoplasms, Article, Young Adult, 03 medical and health sciences, Internal medicine, Biopsy, Biomarkers, Tumor, Humans, In patient, Aged, Chemotherapy, business.industry, lcsh:R, Cancer, medicine.disease, 030104 developmental biology, lcsh:Q, business, Biomarkers, 030217 neurology & neurosurgery, Follow-Up Studies |
| الوصف: | Mammography has a crucial role in the detection of breast cancer (BC), yet it is not limitation-free. We hypothesized that the combination of mammography and cell-free DNA (cfDNA) levels may better discriminate patients with cancer. This prospective study included 259 participants suspected with BC before biopsy. Blood samples were taken before biopsy and from some patients during and at the end of treatment. cfDNA blood levels were measured using our simple fluorescent assay. The primary outcome was the pathologic diagnosis of BC, and the secondary aims were to correlate cfDNA to severity, response to treatments, and outcome. Median cfDNA blood levels were similar in patients with positive and negative biopsy: 577 vs. 564 ng/ml (p = 0.98). A significant decrease in cfDNA blood level was noted after the following treatments: surgery, surgery and radiation, neo-adjuvant chemotherapy and surgery, and at the end of all treatments. To conclude, the cfDNA level could not be used in suspected patients to discriminate BC. Reduction of tumor burden by surgery and chemotherapy is associated with reduction of cfDNA levels. In a minority of patients, an increase in post-treatment cfDNA blood level may indicate the presence of a residual tumor and higher risk. Further outcome assessment for a longer period is suggested. |
| اللغة: | English |
| تدمد: | 2045-2322 |
| DOI: | 10.1038/s41598-020-71357-4 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fce98dab5f360391c56b453fbff8e82 http://link.springer.com/article/10.1038/s41598-020-71357-4 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....0fce98dab5f360391c56b453fbff8e82 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20452322 |
|---|---|
| DOI: | 10.1038/s41598-020-71357-4 |